Last reviewed · How we verify
Levagen+
Levagen+ is a topical formulation containing levamisole that enhances immune function and promotes wound healing through immunomodulatory mechanisms.
Levagen+ is a topical formulation containing levamisole that enhances immune function and promotes wound healing through immunomodulatory mechanisms. Used for Chronic wounds and ulcers, Wound healing promotion.
At a glance
| Generic name | Levagen+ |
|---|---|
| Sponsor | RDC Clinical Pty Ltd |
| Drug class | Immunostimulant |
| Target | Immune cell activation (non-specific) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Wound Care |
| Phase | FDA-approved |
Mechanism of action
Levamisole is an immunostimulant that activates macrophages, enhances T-cell function, and promotes local immune responses. When formulated as Levagen+, it is applied topically to support tissue repair and healing, particularly in chronic or difficult-to-heal wounds. The drug works by restoring impaired immune function at the wound site.
Approved indications
- Chronic wounds and ulcers
- Wound healing promotion
Common side effects
- Local skin irritation
- Allergic contact dermatitis
Key clinical trials
- Training Health Recovery and Improvement Via Levagen+® Evaluation (NA)
- Sleep and Stress Study (PHASE2)
- Long-Term PEA Safety Study (PHASE2)
- Endocannabinoids, Stress, Craving And Pain Effects Study (EARLY_PHASE1)
- Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy (PHASE2)
- Effect of Topical PlexoZome® Levagen® Spray on Relief of Post Exercise Knee Joint Pain (PHASE4)
- Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain (PHASE4)
- Impact of Levagen+® Palmitoylethanolamide (PEA) in a Cross-Over Trial Examining Stress and Cognition in University Students (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levagen+ CI brief — competitive landscape report
- Levagen+ updates RSS · CI watch RSS
- RDC Clinical Pty Ltd portfolio CI